Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.3K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond motor neurons: peripheral TDP-43 pathology in skeletal muscle and intramuscular nerves in amyotrophic lateral sclerosis.

Brain communications·2026
Same author

Modifying disease registries to address the evolving field in rare diseases: the iSMAc/ITASMAc experience in spinal muscular atrophy.

Frontiers in neurology·2026
Same author

The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single <i>SMN2</i> copy: an international retrospective observational study.

EClinicalMedicine·2026
Same author

Emerin is necessary for microtubule-organizing center translocation to the nuclear envelope of muscle cells.

Cell death & disease·2026
Same author

Blood levels of D-aspartate oxidase, D-amino acid oxidase, serine racemase, and pLG72 are influenced by diagnoses of schizophrenia and autism spectrum disorder.

Schizophrenia (Heidelberg, Germany)·2026
Same author

Safety and Tolerability of Givinostat: Evidence From Real-World and Clinical Practice.

Annals of clinical and translational neurology·2026

Related Experiment Video

Updated: Jan 14, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.3K

Decoding inflammatory pathways in spinal muscular atrophy: implications for next-generation therapies.

Linda Ottoboni1,2, Claudio Bruno3,4, Stefania Corti1,5

  • 1Dino Ferrari Center, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milano 20122, Italy.

Brain : a Journal of Neurology
|October 17, 2025
PubMed
Summary

Spinal muscular atrophy (SMA) involves inflammation beyond the nervous system, impacting multiple organs. New therapies must address both SMN protein deficiency and inflammation for better outcomes.

Keywords:
SMN-restoring therapiesanti-inflammatory targetsglial cell dysregulationneuroinflammationspinal muscular atrophysystemic inflammation

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.1K
Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
07:33

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors

Published on: May 1, 2019

12.0K

Related Experiment Videos

Last Updated: Jan 14, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.3K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.1K
Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors
07:33

Conversion of Human Induced Pluripotent Stem Cells iPSCs into Functional Spinal and Cranial Motor Neurons Using PiggyBac Vectors

Published on: May 1, 2019

12.0K

Area of Science:

  • Neuroimmunology
  • Genetics
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is a genetic neurodegenerative disease caused by SMN1 mutations, leading to reduced survival motor neuron (SMN) protein.
  • SMA pathology involves neuroinflammation driven by activated glial and immune cells, affecting neural and non-neural tissues.

Purpose of the Study:

  • To investigate the role of inflammation in SMA pathogenesis.
  • To evaluate the impact of SMN restoration on inflammatory processes.
  • To identify potential therapeutic targets for inflammation in SMA.

Main Methods:

  • Analysis of biological samples from SMA patients and models.
  • Review of preclinical investigations targeting inflammation.
  • Exploration of advanced techniques like single-cell RNA sequencing.

Main Results:

  • SMA exhibits a significant inflammatory footprint with altered immune patterns and elevated inflammatory markers.
  • SMN-restoring therapies may not fully resolve inflammation-related aspects, with mixed outcomes observed.
  • Preclinical anti-inflammatory interventions show promise but require optimized timing.

Conclusions:

  • Inflammation is a critical component of SMA pathology, necessitating targeted therapies.
  • Understanding inflammation timing and mechanisms is key for effective combination treatments.
  • Future research should focus on personalized strategies combining SMN augmentation and anti-inflammatory approaches.